TET proteins regulate T cell and iNKT cell lineage specification in a TET2 catalytic dependent manner.

Translatome and transcriptome analysis of resting B and T cells from mice

Analysis of transcriptomic and epitranscriptomic effects of the acute megakaryoblastic leukemia fusion protein RBM15-MKL1

Direct neuronal reprogramming of mouse astrocytes is associated with multiscale epigenome remodeling and requires Yy1

Joint epigenome profiling reveals cell-type-specific gene regulatory programs in human cortical organoids

Identification of antigen-presenting cell-T cell interactions driving immune responses to food

Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis

Cre-dependent massively parallel reporter assay for cell-type specific assessment of the functional effects of 3'UTR genetic variants in vivo

Targeted high-resolution chromosome conformation capture at genome-wide scale in mouse erythroid cells

Polony gels enable amplifiable DNA stamping and spatial transcriptomics of chronic pain

Ethanol induced transcriptional and translational changes in Aldh1l1-EGFP/Rpl10a cortical astrocyte cultures

Precision targeting of beta-catenin induces tumor reprogramming and immunity in hepatocellular cancers

An activity-specificity trade-off encoded in human transcription factors

Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition

Tissue-specific interferon-gamma levels drive regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer

Expansion of Tumor-Infiltrating CD8+ T Cell Clonotypes Occurs in the Spleen in Response to Immune Checkpoint Blockade

Characterization and function of transcriptional elongation during zygotic genome activation in mouse embryos

LaminB1 DamID, RNA-seq and Genome-wide analysis of replication timing in RIF1 depleted preimplantation mouse embryos

Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma

Transcriptomic studies on ruxolitinib with or without checkpoint inhibitors as a cancer therapy